stockrowRepligen Corporation
RGEN Healthcare Medical Instruments & Supplies
Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024.
- Revenue
- +10.9%
- EPS
- −351.9%
- Free cash flow
- −11.5%
- Total debt
- +3.28%
Quarter to September 2026, against a year earlier
Follow RGEN
Alert me
Repligen Corporation (RGEN) EBITDA
Repligen Corporation's EBITDA for fiscal 2025 was $150.6M, up 200.2% from $50.1M in fiscal 2024. Over the twelve months to 30 September 2026 it was $155.0M. Over the past ten years it has ranged from $18.4M (fiscal 2015) to $277.5M (fiscal 2022); the current reading is higher than 82% of that period. Repligen Corporation ranks 21st of 47 Medical Instruments & Supplies companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $150.6M | 200.23% |
| FY2024 | $50.1M | (57.76%) |
| FY2023 | $118.7M | (57.22%) |
| FY2022 | $277.5M | 27.73% |
| FY2021 | $217.2M | 101.40% |
| FY2020 | $107.9M | 67.26% |
| FY2019 | $64.5M | 40.15% |
| FY2018 | $46.0M | 87.72% |
| FY2017 | $24.5M | 15.04% |
| FY2016 | $21.3M | 16.07% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $25.9M | (44.91%) |
| Jun 2026 | $47.0M | 17.25% |
| Mar 2026 | $40.1M | (4.82%) |
| Dec 2025 | $42.1M | 32.13% |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| SOLV Solventum Corporation compare | $2.6B |
| BAX Baxter International Inc. compare | $1.5B |
| COO The Cooper Companies, Inc. compare | $928.2M |
| AVTR Avantor, Inc. compare | $913.6M |
| ALGN Align Technology, Inc. compare | $802.0M |
| BLCO Bausch + Lomb Corporation compare | $801.0M |
| ATR AptarGroup, Inc. compare | $783.0M |
| TFX Teleflex Incorporated compare | $256.2M |
| RGEN Repligen Corporation | $155.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on RGEN
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement